GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » ROC %

CERo Therapeutics Holdings (CERo Therapeutics Holdings) ROC % : -218.33% (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. CERo Therapeutics Holdings's annualized return on capital (ROC %) for the quarter that ended in Dec. 2022 was -218.33%.

As of today (2024-05-26), CERo Therapeutics Holdings's WACC % is 8.44%. CERo Therapeutics Holdings's ROC % is -218.33% (calculated using TTM income statement data). CERo Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


CERo Therapeutics Holdings ROC % Historical Data

The historical data trend for CERo Therapeutics Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings ROC % Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
ROC %
-193.57 -218.33

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
ROC % -193.57 -218.33

CERo Therapeutics Holdings ROC % Calculation

CERo Therapeutics Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-11.971 * ( 1 - 0% )/( (6.001 + 4.965)/ 2 )
=-11.971/5.483
=-218.33 %

where

CERo Therapeutics Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2022 is calculated as:

ROC % (Q: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2021 ) + Invested Capital (Q: Dec. 2022 ))/ count )
=-11.971 * ( 1 - 0% )/( (6.001 + 4.965)/ 2 )
=-11.971/5.483
=-218.33 %

where

Note: The Operating Income data used here is one times the annual (Dec. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CERo Therapeutics Holdings's WACC % is 8.44%. CERo Therapeutics Holdings's ROC % is -218.33% (calculated using TTM income statement data). CERo Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


CERo Therapeutics Holdings ROC % Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines